AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2205544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic rod (OR) with fluorescein sodium
Number of subjects: 0
Study 2205544 — intervention group
Group type: COMPARATOR
Intervention: Eyedrops (control)
Number of subjects: 0
Study 7253054 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique at the infraumbilical ring
Number of subjects: 0
Study 7253054 — intervention group
Group type: COMPARATOR
Intervention: Closed technique of diagnostic peritoneal lavage
Number of subjects: 0
Study 6507951 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone 125 mg every 6 hours
Number of subjects: 14
Study 6507951 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone 60 mg every 6 hours
Number of subjects: 14
Study 6507951 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocortisone 100 mg every 6 hours
Number of subjects: 14
Study 6507951 — intervention group
Group type: EXPERIMENTAL
Intervention: higher dose glucocorticoid therapy
Number of subjects: 14
Study 31664121 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean Section (CS)
Number of subjects: 30524
Study 31664121 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Birth (VB)
Number of subjects: 30524
Study 26948466 — intervention group
Group type: COMPARATOR
Intervention: Central vein control (CVC)
Number of subjects: 95
Study 26948466 — intervention group
Group type: COMPARATOR
Intervention: Central vein (CV)
Number of subjects: 95
Study 26948466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending aorta (AA)
Number of subjects: 95
Study 25361841 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT programme (Stressbusters)
Number of subjects: 0
Study 25361841 — intervention group
Group type: COMPARATOR
Intervention: Accessing selected websites providing information about low mood/depression (Control)
Number of subjects: 0
Study 22180125 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic group by teleconference
Number of subjects: 0
Study 22180125 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20592128 — intervention group
Group type: EXPERIMENTAL
Intervention: rGH and neridronate (group Bp+rGH)
Number of subjects: 30
Study 20592128 — intervention group
Group type: COMPARATOR
Intervention: neridronate alone (group Bp)
Number of subjects: 30
Study 18801505 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg degarelix followed by monthly injections of 60 mg
Number of subjects: 127
Study 18801505 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg degarelix followed by monthly injections of 80 mg
Number of subjects: 127
Study 18801505 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix treatment
Number of subjects: 127
Study 15695129 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus fenofibrate 160 mg (combination therapy)
Number of subjects: 618
Study 15695129 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg (monotherapy)
Number of subjects: 618
Study 12061948 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 grams daily)
Number of subjects: 27
Study 12061948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no creatine supplementation)
Number of subjects: 27
Study 10822754 — intervention group
Group type: EXPERIMENTAL
Intervention: Weinreb's criteria for classifying blood volume
Number of subjects: 30
Study 10822754 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected venous haematocrit (CVH)
Number of subjects: 30
Study 10822754 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume analysis using direct measurement of cell volume (CV)
Number of subjects: 30
Study 7749823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (equivalent to two drinks per day)
Number of subjects: 34
Study 2135208 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.05 mg/kg)
Number of subjects: 20
Study 2135208 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg oral dose)
Number of subjects: 20
Study 2135208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2135208 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 20
Study 7433978 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 0
Study 7433978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31589610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichiasis surgery (bilamellar tarsal rotation procedure or posterior lamellar rotation procedure)
Number of subjects: 6747
Study 28215759 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Bifidobacterium longum bv. infantis CCUG 52486 combined with gluco-oligosaccharide)
Number of subjects: 112
Study 28215759 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 112
Study 28215759 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV seropositivity
Number of subjects: 112
Study 28215759 — intervention group
Group type: COMPARATOR
Intervention: Synbiotic
Number of subjects: 112
Study 27424812 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (started at enrollment with CD4+ count 350 to 550 cells/mm³)
Number of subjects: 1763
Study 27424812 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART (started after CD4+ counts fell below 250 cells/mm³ or upon AIDS-defining illness)
Number of subjects: 1763
Study 27424812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (early and delayed ART)
Number of subjects: 1763
Study 25122422 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry) using 5A4, ALK1, or D5F3 antibodies; optimized protocols were used after initial results.
Number of subjects: 411
Study 25122422 — intervention group
Group type: COMPARATOR
Intervention: FISH (Fluorescence in situ hybridization) using Vysis' ALK break-apart FISH kit; protocols were standardized across 12 centers.
Number of subjects: 411
Study 25122422 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry) after optimization.
Number of subjects: 411
Study 22266899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2% ropivacaine at 4 mL/hr for 48 hours
Number of subjects: 40
Study 22266899 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study 22266899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.2% ropivacaine
Number of subjects: 40
Study 20122035 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent practice-changing breast cancer updates relevant to older patients
Number of subjects: 0
Study 17160548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 216
Study 17160548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 15724724 — intervention group
Group type: EXPERIMENTAL
Intervention: PspA vaccine
Number of subjects: 0
Study 15724724 — intervention group
Group type: COMPARATOR
Intervention: Strains from SCD patients
Number of subjects: 0
Study 15724724 — intervention group
Group type: COMPARATOR
Intervention: Strains from non-SCD patients
Number of subjects: 0
Study 11157716 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-deficient nontreated patients
Number of subjects: 17
Study 11157716 — intervention group
Group type: COMPARATOR
Intervention: GH-treated patients
Number of subjects: 17
Study 11157716 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 17
Study 9236442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy electrical cardioversion (biphasic shock, 3/3 ms, synchronized to R wave, starting at 60 V, increased in 40-V steps up to 400 V)
Number of subjects: 42
Study 9236442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy electrical cardioversion
Number of subjects: 42
Study 8477412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-40 mg/day)
Number of subjects: 11
Study 8477412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3478996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 20 mg
Number of subjects: 30
Study 3478996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31809262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (Experimental Group)
Number of subjects: 60
Study 31809262 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study 26988693 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (multi-strain microbial cell preparation)
Number of subjects: 136
Study 26988693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 25557387 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training for 8 weeks
Number of subjects: 26
Study 25557387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 23828292 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy exercise (HE)
Number of subjects: 42
Study 23828292 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS exercise (ME)
Number of subjects: 42
Study 23828292 — intervention group
Group type: COMPARATOR
Intervention: MetS control (MC)
Number of subjects: 42
Study 23828292 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC)
Number of subjects: 42
Study 20932706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating platform (RP) total knee arthroplasty
Number of subjects: 69
Study 20932706 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) total knee arthroplasty
Number of subjects: 69
Study 19118696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 423
Study 19118696 — intervention group
Group type: COMPARATOR
Intervention: PDT
Number of subjects: 423
Study 16409564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet dispenser (TD)
Number of subjects: 2296
Study 16409564 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 2296
Study 15223446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy simulator training (PreOp flexible bronchoscopic simulator, Immersion Medical, Gaithersburg, MD)
Number of subjects: 13
Study 15223446 — intervention group
Group type: COMPARATOR
Intervention: No simulator training (Control group)
Number of subjects: 13
Study 15223446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy simulator training
Number of subjects: 13
Study 11480712 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-layer cytology
Number of subjects: 500
Study 11480712 — intervention group
Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 500
Study 8829027 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg BID for up to 3 days)
Number of subjects: 133
Study 8829027 — intervention group
Group type: COMPARATOR
Intervention: prochlorperazine (10 mg BID for up to 3 days)
Number of subjects: 133
Study 1390410 — intervention group
Group type: COMPARATOR
Intervention: Interrupted Mersilene sutures
Number of subjects: 68
Study 1390410 — intervention group
Group type: EXPERIMENTAL
Intervention: Single adjustable running Mersilene suture
Number of subjects: 68
Study 2413835 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.20 mg/kg on days 1 and 2 every 3 weeks for four courses)
Number of subjects: 228
Study 2413835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.15 mg/kg on days 1 and 2 every 3 weeks for four courses)
Number of subjects: 228
Study 2413835 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (cis-platinum and vinblastine for 1 year)
Number of subjects: 228
Study 2413835 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy
Number of subjects: 228
Study 31671258 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI (Percutaneous Coronary Intervention)
Number of subjects: 1000
Study 31671258 — intervention group
Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 1000
Study 30184103 — intervention group
Group type: EXPERIMENTAL
Intervention: Infocalc-2000
Number of subjects: 2000
Study 30184103 — intervention group
Group type: COMPARATOR
Intervention: Negative control with randomly selected markers
Number of subjects: 2000
Study 26745225 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Number of subjects: 59
Study 26745225 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 59
Study 24108668 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (30, 50, or 70 mg)
Number of subjects: 29
Study 24108668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m(2) loading, 250 mg/m(2) maintenance)
Number of subjects: 29
Study 24108668 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 29
Study 24108668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 29
Study 24108668 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 29
Study 22538694 — intervention group
Group type: EXPERIMENTAL
Intervention: LINX® Reflux Management System
Number of subjects: 44
Study 19915181 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine aerosol (0.625, 1.25, 2.5, 5.0, or 10 mg)
Number of subjects: 50
Study 19915181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19915181 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine aerosol
Number of subjects: 50
Study 18399737 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic group psychotherapy
Number of subjects: 18
Study 15800093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 14
Study 15800093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12521318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual nerve protection during lower third molar germectomy
Number of subjects: 300
Study 12521318 — intervention group
Group type: COMPARATOR
Intervention: No lingual nerve protection during lower third molar germectomy
Number of subjects: 300
Study 9841829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, killed enterotoxigenic Escherichia coli (ETEC) plus cholera toxin B subunit vaccine
Number of subjects: 202
Study 7492157 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed whey formula
Number of subjects: 40
Study 7492157 — intervention group
Group type: COMPARATOR
Intervention: Amino acid formula
Number of subjects: 40
Study 7492157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 40
Study 1347204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.06 mg.kg-1
Number of subjects: 0
Study 1347204 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.015 mg.kg-1
Number of subjects: 0
Study 3922823 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg twice a day
Number of subjects: 47
Study 3922823 — intervention group
Group type: EXPERIMENTAL
Intervention: astemizole 10 mg once a day
Number of subjects: 47
Study 3922823 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 29986529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cube sizes of vegetable hash and chicken (0.5, 1.0, and 1.5 cm³) in Study 1 (n = 19)
Number of subjects: 66
Study 29986529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potatoes and mincemeat compared to whole potatoes and meatballs in Study 2 (n = 18)
Number of subjects: 66
Study 29986529 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals served at lunch time (11:00-13:00) compared to identical meals served at dinner time (17:00-19:00) in Study 3 (n = 29)
Number of subjects: 66
Study 28159846 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised CHM
Number of subjects: 40
Study 28159846 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised CHM
Number of subjects: 40
Study 24881281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream, applied twice a day for 4 weeks
Number of subjects: 138
Study 24881281 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream, applied twice a day for 4 weeks
Number of subjects: 138
Study 24881281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 138
Study 24881281 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream
Number of subjects: 138
Study 21214918 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred, structured pharmaceutical care process
Number of subjects: 14200
Study 21214918 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 14200
Study 19324304 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment
Number of subjects: 655
Study 17315118 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric body weight monitoring (TBWM) with weekly reports of weight changes and alarms for IWG greater than 0.75 kg/d
Number of subjects: 120
Study 17315118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TBWM)
Number of subjects: 120
Study 15285314 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol
Number of subjects: 80
Study 15285314 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fentanyl
Number of subjects: 80
Study 15285314 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol
Number of subjects: 80
Study 15285314 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine + fentanyl combination
Number of subjects: 80
Study 11574041 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with severe closed-head injury
Number of subjects: 0
Study 11574041 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with mild head injury
Number of subjects: 0
Study 11574041 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study 9055897 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% glucose solution (1 ml)
Number of subjects: 120
Study 9055897 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose solution
Number of subjects: 120
Study 9055897 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 120
Study 8436151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 144 micrograms.kg‐1
Number of subjects: 48
Study 8436151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 200 micrograms.kg‐1
Number of subjects: 48
Study 8436151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8436151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (various doses)
Number of subjects: 48
Study 8436151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 48
Study 3946953 — intervention group
Group type: COMPARATOR
Intervention: Free-care group
Number of subjects: 3539
Study 3946953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-sharing group
Number of subjects: 3539
Study 3946953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-sharing group (low socioeconomic status, poor health)
Number of subjects: 3539
Study 3946953 — intervention group
Group type: COMPARATOR
Intervention: Free-care group (low socioeconomic status, poor health)
Number of subjects: 3539
Study 30454669 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives up to $60 per participant and nicotine patches
Number of subjects: 2452000
Study 30454669 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus nicotine patches
Number of subjects: 2452000
Study 28076508 — intervention group
Group type: EXPERIMENTAL
Intervention: Swing mesh (n=60)
Number of subjects: 120
Study 28076508 — intervention group
Group type: COMPARATOR
Intervention: Modified Kugel mesh (n=60)
Number of subjects: 120
Study 24885220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination probiotic agent (Lactobacillus rhamnosus and L. helveticus) for 5 days
Number of subjects: 886
Study 24885220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study 21682949 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic depressive symptom dimension at 12 months post-MI
Number of subjects: 2442
Study 21682949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive depressive symptom dimension
Number of subjects: 2442
Study 20231198 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 3 mg/kg q8w
Number of subjects: 76
Study 20231198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 20231198 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 3 mg/kg q8w, with dose escalation to 5 mg/kg if target not met
Number of subjects: 76
Study 18779287 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg/d EPA+DHA
Number of subjects: 302
Study 18779287 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d EPA+DHA
Number of subjects: 302
Study 18779287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 15766995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified blood-pressure control (systolic/diastolic <130/80 mm Hg)
Number of subjects: 338
Study 15766995 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood-pressure control (diastolic <90 mm Hg)
Number of subjects: 338
Study 12001120 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin and 5-fluorouracil) followed by radiotherapy
Number of subjects: 80
Study 12001120 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study 10494606 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha 2a (6 MU, thrice weekly)
Number of subjects: 169
Study 10494606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (14 mg/kg per day) in combination with IFN alpha 2a
Number of subjects: 169
Study 8967579 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic bonded catheters (vancomycin 1 g in 10 ml of water)
Number of subjects: 110
Study 8967579 — intervention group
Group type: COMPARATOR
Intervention: Plain catheters (control group)
Number of subjects: 110
Study 1961962 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 20
Study 1961962 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 20